Spruce Biosciences to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Spruce Biosciences, Inc. (NASDAQ: SPRB) announces participation in the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 5:00 PM EST. CEO Javier Szwarcberg and CFO Samir Gharib will engage in a virtual fireside chat. This company focuses on developing therapies for rare endocrine disorders, particularly its candidate tildacerfont for classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). Interested parties can access the live webcast on the company's investor relations website, with an archived replay available for 30 days.
Positive
None.
Negative
None.
Insights
Analyzing...
SAN FRANCISCO--(BUSINESS WIRE)--
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., MPH, Chief Executive Officer, and Samir Gharib, President and Chief Financial Officer, will participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022 at 5:00pm EST.
Interested parties can access the live webcast for the conference from the Events section of the company’s investor relations website at https://investors.sprucebiosciences.com. An archived replay of the webcast will be available after the conclusion of the live presentation for approximately 30 days.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.
When will Spruce Biosciences participate in the SVB Leerink Global Healthcare Conference?
Spruce Biosciences will participate in the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 5:00 PM EST.
Who are the executives from Spruce Biosciences participating in the conference?
CEO Javier Szwarcberg and CFO Samir Gharib will participate in the conference.
How can I access the Spruce Biosciences conference webcast?
The live webcast can be accessed through the Events section of Spruce Biosciences' investor relations website.
What is the focus of Spruce Biosciences?
Spruce Biosciences focuses on developing therapies for rare endocrine disorders, specifically targeting conditions such as classic congenital adrenal hyperplasia and polycystic ovary syndrome.
Is there a replay available for the Spruce Biosciences conference?
Yes, an archived replay of the webcast will be available for approximately 30 days after the live presentation.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
